BriaCell Therapeutics Corp.

BCTXW

BCTXWBriaCell Therapeutics Corp. US flag

NASDAQ Capital Market

0.50

USD

+0.06

(+14.36%)

9.23MMarket Cap

Apr 30Next Earn

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

BriaCell Therapeutics Corp.

BCTXW

(NASDAQ Capital Market)

Recent

price

0.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

Legends:

Stock price

Beta (1.0 Market)

% total return 12/10

Stock

S&P500

-70.91

30.89

-88.56

28.45

-32.91

92.86

2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	TTM
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Revenue per Share
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Basic EPS, GAAP
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Free Cash Flow per Basic Share
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Dividend per Share
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Book Value per Share
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Tangible Book Value per Share
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Basic Weighted Avg Shares
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Sales/Revenue/Turnover
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Operating Margin (%)
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Depreciation Expense
- -	-1	-1	-1	- -	-8	-3	-2	-3	-4	-5	-4	-14	-27	-20	-5	-5	Net Income, GAAP
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Effective Tax Rate (%)
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Profit Margin (%)
1	1	4	2	1	- -	1	1	1	1	-1	-4	57	41	25	-4	-4	Working Capital
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	LT Debt
1	1	12	10	9	- -	1	1	1	1	-1	-4	28	10	-4	-3	-3	Total Equity
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Return on Invested Capital (%)
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	2,368.23	Return on Capital (%)
- -	- -	- -	- -	-3.98	- -	- -	- -	- -	- -	- -	- -	- -	-173.87	- -	- -	- -	Return on Common Equity (%)

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	- -	- -	- -
Net Income, GAAP	24.5%	44.44%	-76.4%
Free Cash Flow	86.23%	119.51%	3.53%
Total Cash Common Dividend	- -	- -	- -
Total Equity	-10,376.01%	-135%	-28.92%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Similar Companies: Titan Biotech Limited (TITANBIO.BO)
Rapid Dose Therapeutics Corp. (DOSE.CN)
Vaccinex, Inc. (VCNX)
Adocia SA (ADOIF)
Fennec Pharmaceuticals Inc. (FENC)
Enochian Biosciences, Inc. (ENOB)
Business: BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	TTM
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Revenue per Share
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Basic EPS, GAAP
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Free Cash Flow per Basic Share
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Dividend per Share
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Book Value per Share
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Tangible Book Value per Share
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Basic Weighted Avg Shares
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Sales/Revenue/Turnover
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Operating Margin (%)
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Depreciation Expense
- -	-1	-1	-1	- -	-8	-3	-2	-3	-4	-5	-4	-14	-27	-20	-5	-5	Net Income, GAAP
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Effective Tax Rate (%)
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Profit Margin (%)
1	1	4	2	1	- -	1	1	1	1	-1	-4	57	41	25	-4	-4	Working Capital
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	LT Debt
1	1	12	10	9	- -	1	1	1	1	-1	-4	28	10	-4	-3	-3	Total Equity
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Return on Invested Capital (%)
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	2,368.23	Return on Capital (%)
- -	- -	- -	- -	-3.98	- -	- -	- -	- -	- -	- -	- -	- -	-173.87	- -	- -	- -	Return on Common Equity (%)

BriaCell Therapeutics Corp.

Growth Rates

(avg. rate of change)

Working Capital

Capital Structure

Growth Rates

(avg. rate of change)

Quarterly Revenue

Year

Quarterly Earnings Per Share

Year

Quarterly Dividends Per Share

Year

	Jan'24	Apr'24	Jul'24
Total Current Assets	12	6	4
Accounts Receivable, Net	- -	- -	- -
Cash, Cash Equivalents & STI	6	1	1
Inventories	- -	- -	- -
Total Current Liabilities	4	7	7
Payables & Accruals	4	7	7
ST Debt	- -	- -	- -
Deferred Revenue	- -	- -	- -

	Jan'24	Apr'24	Jul'24
ST Debt	- -	- -	- -
LT Borrowings	- -	- -	- -
LT Finance Leases	- -	- -	- -
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	16	16	18
Market Capitalization	- -	- -	- -